UY30461A1 - Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. - Google Patents
Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.Info
- Publication number
- UY30461A1 UY30461A1 UY30461A UY30461A UY30461A1 UY 30461 A1 UY30461 A1 UY 30461A1 UY 30461 A UY30461 A UY 30461A UY 30461 A UY30461 A UY 30461A UY 30461 A1 UY30461 A1 UY 30461A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical composition
- conception
- risk
- reduce
- congenital malformations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Una composicion farmacéutica para la aticoncepcion contiene en una dosis diaria -2,0 mg o 1,5 mg de 17a (alfa)-cianometil-17-b(beta)-hidroxiestra-4,9-dien-3-ona (dienogest) y 0,015 mg de 17S(alfa)-etinilestradiol (etinilestradiol) y (6S)-5-metiltetrahidrofolato, con preferencia como sal de calcio del ácido (6S)-5- metiltetrahidrofolico (metafolina) junto con uno o varios excipientes/vehículos farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06014002 | 2006-07-06 | ||
EP06016950A EP1891959A1 (de) | 2006-08-14 | 2006-08-14 | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30461A1 true UY30461A1 (es) | 2008-02-29 |
Family
ID=38330771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30461A UY30461A1 (es) | 2006-07-06 | 2007-07-04 | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080268048A1 (es) |
EP (1) | EP2037935A1 (es) |
JP (1) | JP2009542588A (es) |
KR (1) | KR20090029824A (es) |
AR (1) | AR061959A1 (es) |
BR (1) | BRPI0713999A2 (es) |
CA (1) | CA2665788A1 (es) |
CL (1) | CL2007001961A1 (es) |
DE (1) | DE112007001600A5 (es) |
IL (1) | IL196154A0 (es) |
MX (1) | MX2009000256A (es) |
PE (1) | PE20080400A1 (es) |
RU (1) | RU2009102443A (es) |
TW (1) | TW200810764A (es) |
UY (1) | UY30461A1 (es) |
WO (1) | WO2008003363A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
MY195019A (en) | 2015-06-18 | 2023-01-03 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
ME03728B (me) | 2015-06-18 | 2021-01-20 | Estetra Sprl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
RS61777B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetrol |
SI3310345T1 (sl) | 2015-06-18 | 2021-05-31 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
EP2002839A1 (en) * | 1998-04-17 | 2008-12-17 | Ortho McNeil Pharmaceutical, Inc. | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
US7696219B2 (en) * | 2000-09-27 | 2010-04-13 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiences in renal patients |
US20020147155A1 (en) * | 2001-04-06 | 2002-10-10 | Foster Warren G. | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands |
PL209558B1 (pl) * | 2002-02-21 | 2011-09-30 | Bayer Schering Pharma Ag | Zestaw zawierający steroid, składnik tetrahydrofolianowy i witaminę B12 do zastosowania w metodzie hormonalnej antykoncepcji lub hormonalnej terapii zastępczej |
DE102004026671A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
AR049065A1 (es) * | 2004-05-28 | 2006-06-21 | Gruenenthal Gmbh | Forma de administracion para la contracepcion hormonal |
UY29527A1 (es) * | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2007
- 2007-05-05 JP JP2009516918A patent/JP2009542588A/ja active Pending
- 2007-05-05 RU RU2009102443/15A patent/RU2009102443A/ru not_active Application Discontinuation
- 2007-05-05 KR KR1020097002387A patent/KR20090029824A/ko not_active Application Discontinuation
- 2007-05-05 BR BRPI0713999-3A patent/BRPI0713999A2/pt not_active Application Discontinuation
- 2007-05-05 MX MX2009000256A patent/MX2009000256A/es not_active Application Discontinuation
- 2007-05-05 WO PCT/EP2007/003982 patent/WO2008003363A1/de active Application Filing
- 2007-05-05 DE DE112007001600T patent/DE112007001600A5/de not_active Withdrawn
- 2007-05-05 EP EP07724906A patent/EP2037935A1/de not_active Withdrawn
- 2007-05-05 CA CA002665788A patent/CA2665788A1/en not_active Abandoned
- 2007-07-03 US US11/773,037 patent/US20080268048A1/en not_active Abandoned
- 2007-07-04 UY UY30461A patent/UY30461A1/es not_active Application Discontinuation
- 2007-07-05 CL CL2007001961A patent/CL2007001961A1/es unknown
- 2007-07-05 PE PE2007000865A patent/PE20080400A1/es not_active Application Discontinuation
- 2007-07-06 TW TW096124769A patent/TW200810764A/zh unknown
- 2007-07-06 AR ARP070103017A patent/AR061959A1/es not_active Application Discontinuation
-
2008
- 2008-12-24 IL IL196154A patent/IL196154A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2007001961A1 (es) | 2008-01-11 |
IL196154A0 (en) | 2009-09-22 |
EP2037935A1 (de) | 2009-03-25 |
DE112007001600A5 (de) | 2009-04-30 |
WO2008003363A1 (de) | 2008-01-10 |
JP2009542588A (ja) | 2009-12-03 |
TW200810764A (en) | 2008-03-01 |
KR20090029824A (ko) | 2009-03-23 |
PE20080400A1 (es) | 2008-07-04 |
CA2665788A1 (en) | 2008-01-10 |
AR061959A1 (es) | 2008-08-10 |
US20080268048A1 (en) | 2008-10-30 |
BRPI0713999A2 (pt) | 2012-11-20 |
MX2009000256A (es) | 2009-02-18 |
RU2009102443A (ru) | 2010-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30461A1 (es) | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. | |
AR061958A1 (es) | Composicion farmaceutica que contiene un acido tetrahidrofolico | |
CL2010000989A1 (es) | Uso de 5-metil-(6s)-tetrahidrofolato, drospirenona y etinilestradiol, en ausencia de viatamina b12, para preparar un medicamento util para prolongar la reduccion del riesgo de enfermedades y malformaciones congenitas provocadas por carencias de folato seleccionadas de grupo definido (sol.div. 1130-06). | |
AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
CL2011003172A1 (es) | Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos. | |
UY33343A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
PE20070192A1 (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
MX2010007083A (es) | Combinacion anti-retroviral. | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
EA201171497A1 (ru) | Снижение флуктуаций опиоидов в крови | |
ECSP077263A (es) | ||
CL2010001471A1 (es) | Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. | |
CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
CR10912A (es) | Preparacion framaceutica para reducir la endometriosis | |
CL2007002788A1 (es) | Un compuesto derivado de (cis)-8-fluorodibenzo[b,f]pirido[1,2-d]oxazepin-1-amina, modulador de los receptores de progesterona; composicion farmaceutica; y uso como anticonceptivo, para la terapia de reemplazo hormonal o para el tratamiento de un tras | |
DOP2007000122A (es) | Forma farmacologica peroral para anticoncepcion | |
DOP2007000117A (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
CL2008001147A1 (es) | Combinacion farmaceutica que comprende 11b-(4-acetilfenil)-17b-hidroxi-17 (1,1,2,2,2-pentafluoroetil) estra-4,9-dien-3-ona junto con al menos un antiestrogeno no esteroidal puro; y uso para la profilaxis o el tratamientodel cancer mediado por brca1 o brca2. | |
MX2010002190A (es) | Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo | |
PE20091020A1 (es) | Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa | |
UY29378A1 (es) | Preparación farmaceutica para la anticoncepción oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170720 |